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Abstract
Background: Evolution of indolent to aggressive lymphoma has been described in dogs but is difficult to
distinguish from the de novo development of a second, clonally distinct lymphoma. Differentiation of these
scenarios can be aided by next generation sequencing (NGS)-based assessment of clonality of lymphocyte antigen
receptor genes.
Case presentation: An 8-year-old male intact Mastiff presented with generalized lymphadenomegaly was
diagnosed with nodal T zone lymphoma (TZL) based on cytology, histopathology, immunohistochemistry and flow
cytometry. Thirteen months later, the dog re-presented with progressive lymphadenomegaly, and based on
cytology and flow cytometry, a large B cell lymphoma (LBCL) was diagnosed. Sequencing-based clonality testing
confirmed the de novo development of a LBCL and the persistence of a TZL.
Conclusions: The occurrence of two distinct lymphoid neoplasms should be considered if patient features and
tumor cytomorphology or immunophenotype differ among sequential samples. Sequencing-based clonality testing
may provide conclusive evidence of two concurrent and distinct clonal lymphocyte populations, termed most
appropriately “composite lymphoma”.
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Background
Lymphoma is the most common hematopoietic neo-
plasm in dogs and is due to clonal proliferation of lym-
phocytes [1]. The clinical features of lymphoma vary
widely, and range from slowly progressive indolent
forms with modest tumor burden to rapidly progressive
forms with large tumor burden and profound general ill-
ness [2, 3]. Attempts have been made to predict the clin-
ical progression of lymphoma for accurate prognosis and
appropriate therapy. Adaptation of the World Health
Organization’s classification scheme for lymphoma in
humans to samples of lymphoma from dogs identified
six major entities [4]. Among these were diffuse large B
cell lymphoma (DLBCL) and T zone lymphoma (TZL),
which are defined by tumor architecture, histomorphol-
ogy and immunophenotype [4]. Diffuse large B cell
lymphoma is characterized by high mitotic count, ex-
pression of the B cell antigens CD79a, CD20 and/or
CD21, and rapid progression [5]. TZL is typically associ-
ated with slowly enlarging lymph nodes, low-grade lym-
phocytosis, and expression of T cell antigens such as
CD3, CD5, and/or CD4 or CD8 [2, 6].
Approaches to diagnose and classify lymphoma in-
clude cytology, histopathology, immunohistochemistry,
flow cytometry, and clonality testing. Although histo-
pathology combined with immunohistochemistry is gen-
erally sufficient for diagnosis, obtaining a tissue biopsy
requires sedation or anesthesia. Aspirating lymph nodes
is less invasive, and since most lymphomas in dogs have
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diffuse architecture, representative samples for diagnosis
are readily obtained. Aspirated samples are also suitable
for flow cytometric characterization and, therefore, prog-
nostication [7]. In cases of lymphomas with mixed cell
composition, or unusual histomorphology, additional
testing such as clonality assessment, may be required.
Clonality testing, in veterinary medicine also known as
polymerase chain reaction (PCR) for antigen receptor
gene rearrangement (PARR), detects rearranged antigen
receptor genes by PCR-based amplification and evalu-
ation of amplicon sizes by high-resolution electrophor-
etic analysis [8]. Both flow cytometry and clonality
testing can be used for confirmation or classification of
canine lymphoma, but infidelity in lymphocyte antigen
expression and clonal rearrangements has also been
identified in non-lymphoid neoplasms of dogs [9]. Fur-
thermore, robust data concerning sensitivity and specifi-
city of either assay are limited. With next generation
sequencing (NGS)-based clonality testing, thousands to
millions of lymphocyte antigen receptor gene sequences
amplified in a single run are analyzed quantitatively.
This technology, while more complex and expensive, cir-
cumvents certain shortcomings of conventional clonality
assays such as interpretative subjectivity of electrophor-
etic peaks and false positive results from presence of
multiple clones of similar size. Since NGS-based clonal-
ity testing identifies clones by sequence, this method-
ology allows monitoring of patient-specific tumor clones
during and after therapy, an application known as min-
imal residual disease (MRD) monitoring [10].
This is the first report of a dog with concurrent TZL
and LBCL diagnosed using multiple diagnostic ap-
proaches. Clinical features and tumor cytomorphology
suggested emergence of a high-grade lymphoma in a pa-
tient with a pre-existing indolent TZL. Flow cytometry
confirmed the initial subtype of TZL and subsequent
LBCL, and NGS-based clonality testing identified two
distinct clones within one affected lymph node.
Case presentation
An 8-year-old male intact Mastiff presented to a veterin-
ary specialty hospital with an acute onset of head shaking.
Magnetic resonance imaging (MRI) of the head revealed
an intra-axial lesion within the right pyriform lobe. The le-
sion was T2/FLAIR hyperintense, T1 hypointense, and
non-contrast enhancing with a mild mass effect, consist-
ent with a primary neoplasm such as glioma. The dog was
subsequently referred to the Ontario Veterinary College
Animal Cancer Centre, and definitive radiation therapy
consisting of 18 fractions was administered over 4 weeks
at a total dose of 45 Gray.
At a re-check appointment 7 months after completion
of radiation therapy, the dog was free of neurological
signs while receiving solely oral phenobarbital (120 mg,
q12h) but physical examination revealed mild general-
ized lymphadenomegaly. Results of a complete blood cell
count (CBC) and serum biochemistry analysis were un-
remarkable. Fine needle aspirates of three peripheral
lymph nodes yielded slides with a relatively uniform
population of medium size lymphocytes with pale cyto-
plasm, central or slightly eccentric nuclei and frequent
cytoplasmic projections. The findings were interpreted
as lymphoma, and the cytomorphology was consistent
with TZL [11] (Fig. 1a and b). Histopathology of an exci-
sional biopsy of the left popliteal lymph node showed a
paracortical expansion in between “fading” follicles with
monotypic lymphocytes arranged in sheets with minimal
anisocytosis and absent mitotic figures (Fig. 1c and d).
Immunohistochemically, the neoplastic cells had faint
cytoplasmic and membranous reactivity for CD3 and
lacked CD79a and granzyme B immunoreactivity (Fig. 1e
and f), confirming the diagnosis of TZL. A lymph node
aspirate submitted for flow cytometry showed that lym-
phocytes were highly positive with antibodies to CD5
and MHC II, while detection of CD3 and CD45 was dim
and absent, respectively [12] (Fig. 1g). Abdominal ultra-
sound findings were unremarkable, and MRI of the brain
showed approximately 50% reduction in size of the
intracranial lesion. Due to the indolent nature of TZL
and the patient being well, monitoring without specific
therapy was recommended.
Nine months following the diagnosis of TZL, the
patient was presented again due to lethargy and dull-
ness, and mild to moderate generalized peripheral
lymphadenopathy was noted. The results of a CBC
and serum biochemistry analysis were again unre-
markable, and an MRI of the brain was performed.
Mild obstructive hydrocephalus attributed to an intra-
medullary lesion in the cranial cervical spine with
meningeal enhancement was noted. There was no ap-
parent progression of the previously identified intra-
cranial neoplasm. Therapy with prednisone (1 mg/kg
q24h) was initiated with the intent to alleviate edema
and hydrocephalus. The dog’s lethargy and dullness
improved; however, reduction in prednisone dosage
over the subsequent weeks resulted in recurrent mal-
aise. Therefore, a maintenance prednisone dosage of
0.7 mg/kg q48h was prescribed.
Two months later, the owner noted progressive per-
ipheral lymphadenomegaly, which was confirmed during
physical examination at the teaching hospital. The
marked increase in lymph node size was interpreted as
progression of the TZL, and chemotherapy with chlor-
ambucil (4 mg/m2 q24h) was added to prednisone. Three
weeks later, the owners reported that an episode of pain
and weakness had occurred at home, which prompted
an increase in prednisone dosage to 1 mg/kg q24h. The
owners noted no further episodes.
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At a recheck assessment 6 weeks following the start of
chlorambucil therapy, lymphadenomegaly was un-
changed. The dosage of chlorambucil was increased to
20mg/m2 q14d. Eleven days later the dog was re-
admitted due to hyporexia, lethargy and progressive lym-
phadenomegaly. Moderate neutrophilia with mild left
shift and biochemical abnormalities consistent with a
steroid hepatopathy were noted on bloodwork (Add-
itional file 1: Table S1), and abdominal ultrasound re-
vealed medial iliac and inguinal lymphadenomegaly, and
diffuse nodular hepatopathy. Cytologic evaluation of a
prescapular lymph node aspirates showed a homoge-
neous population of large lymphocytes with intensely
basophilic cytoplasm, central to slightly eccentric nuclei
and indistinct paranuclear clear zones, which was inter-
preted as a large cell lymphoma (Fig. 2a). On flow cy-
tometry, the cells were highly positive for CD21, CD45
and MHC II and negative for CD3, CD4, CD5 and CD8,
consistent with a diagnosis of LBCL (Fig. 2b). There was
also a population of small lymphocytes, and these lym-
phocytes expressed a similar constellation of antigens as
those of the prior TZL (data not shown). The dog was
hospitalized and 10,000 IU of L-asparaginase, 0.2 mg/kg
of dexamethasone and 0.7 mg/m2 of vincristine were ad-
ministered. Lymph node size decreased within 24 h, but
the owners elected not to continue with further therapy,
and no additional anti-neoplastic therapy was instituted.
The dog was euthanized by intravenous pentobarbital in-
jection at the primary veterinary clinic 2 months follow-
ing the diagnosis of LBCL (15 months after diagnosis of
TZL) due to progressive lethargy, weakness, and lympha-
denomegaly. An necropsy was not performed.
To investigate a potential relationship between the ini-
tial TZL and subsequent LBCL, NGS-based clonality
testing was performed after euthanasia using DNA ex-
tracted from lymph node samples collected at the time
of diagnosis of each lymphoma (Figs. 3 and 4; Additional
file 2: Table S2). The initial sample diagnosed as TZL
yielded polyclonal results with primers targeting the im-
munoglobulin heavy chain (IGH) locus (Fig. 3c), and
clonal rearrangements in a polyclonal background with
primers targeting the T cell receptor gamma (TRG) (Fig.
3b) and T cell receptor beta (TRB) (Fig. 3a) loci. The
dominant TRB clone was productive and utilized the
genes TRBV16/TRBJ2–1. The TRG repertoire contained
two dominant clones of approximately equal abundance,
both of which were unproductive and utilized TRGV2/
TRGJ3–2. The subsequent sample from the time of
LBCL diagnosis yielded virtually identical results for the
T cell loci compared to the initial sample. The same
TRB and TRG clones were present in a polyclonal back-
ground (Fig. 3d-e), suggesting that the TZL had per-
sisted. In contrast to the initial sample, the second
sample gave a clear-cut clonal result for the IGH locus
(Fig. 3f). The dominant clone was productive and uti-
lized genes IGHV3–6/IGHJ3. No dominant clones were
seen for any loci in the lymph node control (Fig. 3g-i).
Discussion and conclusions
This report describes the emergence of LBCL in a dog
with pre-existent and persistent TZL. In human oncol-
ogy, presence of two distinct, clonally unrelated, lymph-
omas within the same organ is termed “composite
lymphoma”. This entity comprises < 5% of all lymph-
omas in humans [13], but has not previously been re-
ported in dogs. The diagnosis of composite lymphoma
requires morphological, immunohistochemical, and mo-
lecular assessment [13]. In the case reported here, this
diagnosis was based on the dissimilar cytomorphological
and immunophenotypic features of the tumors as well as
the two distinct clonal signatures determined by NGS-
based clonality testing. Transformation of indolent
hematologic neoplasms into more aggressive forms, such
as chronic lymphocytic leukemia into high-grade lymph-
oma, has previously been reported, and appears to occur
occasionally in dogs [14–16]. However, in this case, the
combined evidence of multiple testing modalities
strongly suggests the concurrence of two distinct lymph-
omas rather than evolution of an indolent lymphoma
into a more aggressive variant.
Differentiating relapse from development of a de novo
tumor is challenging for most cancer types. Lymphoid
cancers differ in this regard because every lymphocyte
clone carries a unique DNA sequence that can be used
as a genetic fingerprint to track lymphocyte clones over
time and across anatomic sites. This unique gene se-
quence is generated early in lymphocyte development by
rearrangement of antigen receptor genes, and confers
every lymphocyte clone with unique antigen specificity.
Clonality testing assesses the diversity of lymphocyte
(See figure on previous page.)
Fig. 1 a An aspirate of an enlarged popliteal lymph node consists of a predominant population of small lymphocytes that have a moderate
amount of pale cytoplasm. b At higher magnification frequent cytoplasmic fragments and “hand-mirror” appearance of cells are evident. c On
histopathology, cortico-medullary distinction of the lymph node is distorted by an expansion of paracortical lymphocytes (bracket). d At higher
magnification, mitotic figures are absent. e With immunohistochemistry, there is faint cytoplasmic and membranous reactivity for CD3 on the
neoplastic cells and absent reactivity on a remnant follicle (*), while in f reactivity for CD79a is absent on neoplastic cells but prominent on a
remnant follicle (*). g On flow cytometry, small lymphocytes are uniformly positive for CD5 and MHC II, and negative for CD4, CD8, CD21 and
CD45. There is dim detection of CD3. These findings are consistent with TZL
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antigen receptor genes in a given lymphocyte popula-
tion. In the initial sample, clonality testing confirmed
the diagnosis of TZL based on the presence of clonal
TRB and TRG rearrangements. A single productive TRB
rearrangement and two unproductive TRG rearrange-
ments were consistent with an alpha/beta T cell lineage
of the neoplastic clone, and usage of TRGV2/TRJ3–2 by
both dominant clones was suggestive of a bi-allelic
rearrangement rather than the rearrangement of two dif-
ferent cassettes on the same chromosome. The same re-
arrangements were found in the second sample at
similar abundance, which suggests persistence of the
neoplastic T cell clone in the face of treatment. In
addition to the clonal TRB and TRG rearrangements,
the second sample showed a dominant IGH clone that
comprised about 88% of all rearrangements. This finding
Fig. 2 Popliteal lymph node aspirate 13 months after sample in Fig. 1 was obtained. a The lymphocytes are large and round with intensely
basophilic cytoplasm, and prominent, mostly single, large nucleoli. b On flow cytometry, a prominent population of large lymphocytes is
apparent, and these lymphocytes are highly positive for CD21, MHC II and CD45. These findings are typical of DLBCL
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Fig. 3 Sequencing-based clonality test results, analysed and visualized by ARResT/Interrogate (http://arrest.tools/interrogate), from replicate
samples diagnosed as TZL (a-c), ‘composite’ TZL and LBCL (d-f), and from a reactive lymph node of a different patient (g-i). X-axis: amino acid
length of junctional region, double bars per junction length represent replicates; Y-axis: abundance of clones. The 100 most abundant clones are
displayed as colored slices of a bar, less abundant clones are grey. Identical colors within one subfigure represent identical clonotypes. Dominant
clones in a polyclonal background are visible for the TRB and TRG loci in the TZL sample, and in the TZL/LBCL sample. For the IGH locus,
polyclonal results were obtained for the TZL sample and a clonal result for the TZL/LBCL sample. The reactive lymph node control sample gave
polyclonal results for all loci (g-i). Bars with colored arrows are highlighted in Fig. 4
Fig. 4 Network diagrams reflecting the junctional sequence homology of the most abundant clones with a given junctional length (TRB: 13
amino acids; IGH: 20 amino acids) for the TZL (top row) and the TZL/LBCL (bottom row) in replicate. Bubble size corresponds to read abundance.
Smaller bubbles superimposed on dominant clones represent clones with similar sequence and likely reflect true biological sequence variation as
well as PCR and sequencing errors. Border colors correspond to the arrow colors in Fig. 3
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not only confirms the diagnosis of a B cell lymphoma
but also suggests that the B cell lymphoma is a de novo
tumor rather than a progression of the TZL with altered
immunophenotype. In contrast to cell surface marker
expression, which can be influenced by micro-
environmental stimuli and a cell's developmental stage
and viability, lymphocyte antigen receptor gene rear-
rangements are stable throughout the life of a lympho-
cyte [17]. Consequently, if the B cell lymphoma had
been a transformed progression of the previously diag-
nosed TZL, then the dominant IGH clone detected in
the second sample would have had to be present in the
initial sample. However, the initial sample had a diverse
polyclonal B cell repertoire, and the sequence of the
clonal IGH rearrangement was not detected in the initial
sample.
The use of sequencing-based clonality testing provided a
distinct advantage over electrophoresis-based methods.
Traditionally, clonality testing utilizes gel electrophoresis
to visualize the diversity of lymphocyte antigen receptor
gene arrangements in a given sample. Since this method
only distinguishes antigen receptor genes by size, it can re-
sult in equivocal results when the signal of a neoplastic
clone is quenched by noise of non-neoplastic lymphocytes.
Sequencing-based clonality testing yields a higher ‘clonal
resolution’ because it can distinguish lymphocyte clones
based on sequence on top of size [18, 19]. In this study,
sequencing-based testing readily identified TRB and TRG
clones in both samples despite the presence of a polyclonal
background. Furthermore, identification of the TRB and
TRG gene sequences of the neoplastic clone unequivocally
determined that the dominant T cell clone was identical in
both samples. Identifying clones by gene sequence confers
a higher confidence in both clones being identical than if
clones are identified by size only. Another advantage of
NGS-based clonality testing is that once the sequence of a
neoplastic clone has been determined, it can be traced in
samples even if it comprises a minute fraction of all rear-
rangements [10]. In the current case, identification of the
IGH gene sequence of the LBCL in the second sample
allowed searching for this ‘index sequence’ in the initial
sample. The fact that the IGH index sequence could not
be found in the initial sample strongly suggests that this B
cell clone was not present at the time when the TZL was
initially diagnosed. Of note, the sensitivity of detecting an
index clone is highly dependent on the sequencing depth.
Although NGS was useful to identify the presence of two
distinct clones in this case, other diagnostic approaches were
also necessary. An entire affected lymph node was initially
removed and assessed histopathologically and immunohisto-
chemically to confirm the cytological diagnosis of TZL. Sec-
tions consisted of a homogeneous population of small
lymphocytes with rare remnant follicles. Cytologic evalu-
ation of an aspirate of the contralateral popliteal lymph node
collected 1 year after the initial sample identified cells mor-
phologically consistent with LBCL rather than TZL, which
prompted immunophenotypic assessment. Flow cytometry
confirmed LBCL, which in virtually all cases in dogs is a
DLBCL [4]. Although histopathological assessment of the af-
fected lymph node was not performed, the flow cytometric
findings of CD21, CD45 and MHC II positivity combined
with large cell size were highly consistent with the diagnosis
of DLBCL [20]. Among lymphomas in dogs, TZL is a
unique entity since even without therapy the neoplasm may
not progress at all or only slowly; there is a strong breed pre-
dilection; the pan-leukocyte antigen CD45 is typically un-
detectable on tumor cells; and the B cell antigen CD21 may
be present at low level [6]. Furthermore, cells with this
immunophenotype have been identified in older Golden
Retriever dogs without evidence of lymphoid neoplasia, and
some of these dogs also were reported to have clonal T cell
populations [21]. Of note, the resolution of clonal peaks with
electrophoresis-based methods is lower than with
sequencing-based methods, and it is conceivable that clonal
populations identified by electrophoresis may be more di-
verse if assessed by sequencing. Therefore, many aspects of
the biology of TZL remain incompletely characterized.
It is possible that the dog in this report had an in-
creased risk of developing secondary neoplasms follow-
ing radiation of the brain tumor. Radiation therapy
induces a multitude of adverse effects, including sys-
temic effects from local therapy [22]. Such effects can
compromise the immune system, which in turn might
reduce immune surveillance and increase the risk of sub-
sequent cancer development. While in humans tumor ir-
radiation is most often associated with secondary
myeloid neoplasms, similar associations in dogs are un-
determined [23]. In general, knowledge of genetic lesions
underlying lymphomagenesis in dogs is sparse, and a
limited set of mutations was more highly associated with
breed than with lymphoma type [24].
Treatment and prognosis of composite lymphoma in
humans varies depending on histological subtype [13].
Canine TZL has an indolent disease course, but DLBCL
is an aggressive lymphoma with median progression free
survival of 251–252 days, when treated with combination
chemotherapy [5, 25]. Induction therapy for the dog in
this report was a standard dose of L-asparaginase and
vincristine, but a durable clinical response was not ex-
pected due to the prior long-term exposure to glucocor-
ticoids [26]. Unfortunately, despite an initial favorable
response, therapy was not continued, and outcome could
not be fully assessed.
The patient had been diagnosed with an intracra-
nial mass most consistent with glioma several months
prior to the first diagnosis of lymphoma. Without
histopathologic evaluation, non-neoplastic causes of
brain masses such as vascular events or
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granulomatous inflammation cannot be entirely ruled
out. However, the clinical features and MRI charac-
teristics of intra-axial location, T2/FLAIR hyperinten-
sity, T1 hypointensity, lack of contrast enhancement,
and mass effect, were most suggestive of a neoplasm
such as a low-grade glioma [27–29]. Definitive radi-
ation therapy resulted in at least 16 months of object-
ive tumor response in this patient, which is similar
or slightly longer than reported for other intra-axial
tumors [30, 31].
Limitations to this investigation were the unavail-
ability of a biopsy from the lymph node with concur-
rent TZL/LBCL, and lack of post mortem assessment.
Histopathology and immunohistochemistry of the sec-
ond lymphoma would have allowed more definitive
diagnosis of LBCL, and illustrated morphological find-
ings associated with concurrent TZL and LBCL. Simi-
larly, post mortem evaluation would have allowed
conclusive identification of the brain lesion and the
extent of the lymphoma. Nevertheless, evidence for a
composite lymphoma in this case was considered very
strong based on multiple sophisticated and comple-
mentary diagnostic approaches.
In conclusion, this report of a composite lymph-
oma in a dog highlights the value of multiple diag-
nostic approaches to differentiate between two de
novo lymphomas rather than transformation of a
single clone.
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